Goethe University Frankfurt
- Address
- Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
TSC‑Related Epilepsy Research
At the Epilepsy Center Frankfurt Rhine-Main, investigators are focusing on Tuberous Sclerosis Complex–related seizures, exploring new options to improve long‑term control for both children and adults.
- Long‑term safety and tolerability evaluation
- Adjunctive therapy with Ganaxolone
- Inclusion of pediatric and adult populations
- Monitoring of seizure frequency and quality of life
The program underscores Goethe University Frankfurt’s commitment to advancing treatments for nervous system disorders.
Targeted Therapy for H3 K27M‑Mutant Diffuse Glioma
Researchers are evaluating a precision approach for patients with H3 K27M‑mutant diffuse glioma, aiming to enhance outcomes after standard radiotherapy.
- Molecularly driven drug assessment
- Post‑radiation maintenance strategy
- Exploration of survival benefit
- Integration of biomarker analysis
The study highlights the site’s expertise in neuro‑oncology within the broader neoplasm therapeutic area.
Vaccination Approach for Recurrent Glioblastoma and Astrocytoma
A novel immunotherapy trial is testing the CVGBM vaccine in patients who have undergone surgery for glioblastoma or astrocytoma, seeking to prevent tumor recurrence.
- Dose‑escalation safety assessment
- Evaluation of immune response activation
- Post‑surgical adjuvant treatment model
- Comprehensive adverse‑event monitoring
This effort reflects the center’s dedication to innovative cancer therapies within the neoplasms research portfolio.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 29 therapeutic areas and 15 of 748 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 705 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 151 by active trials.
- 1Novartis Pharma AG12active
lock +150 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG28trials
lock +103 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Goethe University Frankfurt
lock Showing 1 of 620 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 748 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 35 | Unknown | 2018-03-06 | 2026-06-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.